Michel Lagarde

Title: Michel Lagarde: Innovator in Diabetic Retinopathy Treatment

Introduction

Michel Lagarde is a notable inventor based in Chassieu, France. He has made significant contributions to the field of medical research, particularly in the treatment of diabetic retinopathy. With a total of 3 patents to his name, Lagarde's work has the potential to impact the lives of many individuals suffering from this condition.

Latest Patents

One of Lagarde's latest patents focuses on methods of treating diabetic retinopathy with pericyte apoptosis inhibitors. This innovative method involves administering a therapeutically effective amount of an inhibitor of retinal pericyte apoptosis to a mammal. Additionally, he has developed a pharmaceutical composition that treats and/or prevents diabetic retinopathy, which includes a therapeutically effective amount of at least one inhibitor of retinal pericyte apoptosis along with a pharmaceutically acceptable carrier. Another area of his research includes polyunsaturated fatty acid-based drugs, which further showcases his commitment to advancing medical treatments.

Career Highlights

Throughout his career, Michel Lagarde has worked with esteemed organizations such as the Institut National de la Santé et de la Recherche Médicale and Nestec S.A. His experience in these institutions has allowed him to refine his research skills and contribute to groundbreaking innovations in the medical field.

Collaborations

Lagarde has collaborated with notable professionals in his field, including Helmut Traitler and Hans-Juergen Wille. These partnerships have likely enriched his research and expanded the scope of his inventions.

Conclusion

Michel Lagarde's contributions to the treatment of diabetic retinopathy through innovative methods and pharmaceutical compositions highlight his role as a significant inventor in the medical field. His work continues to pave the way for advancements in healthcare and patient treatment.